Otenabant (CP-945,598) is a drug that acts as a potent and highly selective
CB1antagonist.[1] It was developed by
Pfizer for the treatment of
obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug
rimonabant.[3]
^Kim MA, Yun H, Kwak H, Kim J, Lee J (2008). "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist". Tetrahedron. 64 (48): 10802–10809.
doi:
10.1016/j.tet.2008.09.057.
^Woods SC (November 2007). "The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction". Journal of the American Academy of Physician Assistants. Suppl Endocannabinoid (11): 7–10.
doi:
10.1097/01720610-200711000-00005.
PMID18047036.
S2CID25472128.